Cure My Disease

Don't miss your cure!

 Log in / Sign up

Head-to-Head: which biologic works better for tough psoriatic arthritis?

NCT ID NCT04632927

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two biologic drugs, secukinumab and ustekinumab, in 119 adults with active psoriatic arthritis who had not responded to or could not tolerate TNFα-inhibitor treatment. The main goal was to see which drug better improved physical function over 28 weeks. Researchers also looked at skin clearance and other outcomes. The trial is complete, and results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Secukinumab (a biologic drug) and Ustekinumab (a biologic drug)

What this could lead to

If secukinumab works better than ustekinumab, it could offer a new treatment option for people with psoriatic arthritis who have not responded to other therapies.

What could go wrong

This is a completed Phase 3 trial with 119 participants, so results are more reliable than early-phase studies. However, individual responses vary, and both drugs have known side effects like increased infection risk.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIATIC ARTHRITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIATIC ARTHRITIS

Contacts and locations

Locations

  • Novartis Investigative Site

    Rendsburg, Schleswig-Holstein, 24768, Germany

  • Novartis Investigative Site

    Aachen, 52074, Germany

  • Novartis Investigative Site

    Bad Bentheim, 48455, Germany

  • Novartis Investigative Site

    Bad Doberan, 18209, Germany

  • Novartis Investigative Site

    Berlin, 12435, Germany

  • Novartis Investigative Site

    Berlin, 13125, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Bochum, 44791, Germany

  • Novartis Investigative Site

    Cologne, 50937, Germany

  • Novartis Investigative Site

    Cologne, 51149, Germany

  • Novartis Investigative Site

    Cottbus, 03042, Germany

  • Novartis Investigative Site

    Dresden, 01067, Germany

  • Novartis Investigative Site

    Dresden, 01307, Germany

  • Novartis Investigative Site

    Ehringshausen, 35630, Germany

  • Novartis Investigative Site

    Erlangen, 91056, Germany

  • Novartis Investigative Site

    Frankfurt, 60590, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, 79106, Germany

  • Novartis Investigative Site

    Gommern, 39245, Germany

  • Novartis Investigative Site

    Göttingen, 37075, Germany

  • Novartis Investigative Site

    Hamburg, 22391, Germany

  • Novartis Investigative Site

    Herne, 44649, Germany

  • Novartis Investigative Site

    Leipzig, 04103, Germany

  • Novartis Investigative Site

    Magdeburg, 39104, Germany

  • Novartis Investigative Site

    Magdeburg, 39110, Germany

  • Novartis Investigative Site

    Mainz, 55131, Germany

  • Novartis Investigative Site

    München, 81541, Germany

  • Novartis Investigative Site

    Planegg, 82152, Germany

  • Novartis Investigative Site

    Ratingen, 40878, Germany